UCLA starts Phase I stem cell trial for cancers with NY-ESO-1 tumour marker
The University of California, Los Angeles (UCLA) has started a Phase I clinical trial to evaluate new genetically engineered blood-forming stem cells to treat cancers such as melanoma and sarcoma with a specific tumour marker called NY-ESO-1.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Genetics | Melanoma | Pharmaceuticals | Sarcomas | Skin Cancer | Stem Cell Therapy | Stem Cells